NICE TA695 recommends Carfilzomib plus lenalidomide and dexamethasone is recommended as an option for treating multiple myeloma in adults, only if they have had only 1 previous therapy, which included bortezomib.
Carfilzomib with dexamethasone is recommended as an option for treating multiple myeloma in adults, only if they have had only 1 previous therapy. NICE TA657 November 2020
Carfilzomib (Kyprolis BLACK TRIANGLE DRUG): risk of reactivation of hepatitis B virus-NOV 19
Establish hepatitis B status before initiating carfilzomib and in patients with unknown hepatitis B virus serology who are already being treated with carfilzomib
Drug safety update; Carfilzomib (KyprolisBLACK TRIANGLE DRUG): reminder of risk of potentially fatal cardiac events
Anti-cancer therapy with carfilzomib has been associated with cases of cardiac arrest, cardiac failure, and myocardial infarction, including in patients without pre-existing cardiac disorders.